News

Fulranumab Shows Efficacy for Osteoarthritis Pain

Publish date: July 8, 2011

 

FROM THE ANNUAL EUROPEAN CONGRESS OF RHEUMATOLOGY

Dr. Thipphawong and several of his associates are employees of Johnson & Johnson, the company developing fulranumab.

Pages

Recommended Reading

Methadone: Safe Prescribing for Chronic Pain
MDedge Internal Medicine
Opioid Rotation: Focus on Safety
MDedge Internal Medicine
Tocilizumab Safety Confirmed in Real-World Setting for RA
MDedge Internal Medicine
Topical Combo Shows Early Promise in Moderate Psoriasis
MDedge Internal Medicine
ACPA-Negative RA Incidence Spikes During First Postpartum Year
MDedge Internal Medicine
Rheumatoid Arthritis Patients Have High Expectations for Biologics
MDedge Internal Medicine
Periprosthetic Joint Infections Not Increased by RA Biologics
MDedge Internal Medicine
GI Perforation Rare in Rheumatoid Arthritis Patients
MDedge Internal Medicine
RA and SLE Risk Factors Remain for Mothers and Babies
MDedge Internal Medicine
SLE: Belimumab Safety, Efficacy Sustained Over 6 Years
MDedge Internal Medicine